Open AccessClinical Outcome in Patients with Carcinoma of the Esophagogastric Junction Treated with Neoadjuvant Radiochemotherapy or Perioperative Chemotherapy: A Two-Center Retrospective Analysis
Author(s) -
Helwig Wundsam,
Bernhard Doleschal,
Regina Prommer,
Clemens Venhoda,
Clemens A. Schmitt,
Andreas Petzer,
Sigrid Metz-Gercek,
Holger Rumpold
Publication year - 2020
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000507706
Subject(s) - medicine , perioperative , surgery , neoadjuvant therapy , exact test , cohort , oncology , cancer , breast cancer
Adenocarcinoma of the esophagogastric junction (AEG) is a rare but rising tumor entity in the Western world. Treatment is complex, as multimodality is key to optimal results. However, trials solely including AEG are rare, and the question if neoadjuvant radiochemotherapy (NRCT) or neoadjuvant/perioperative chemotherapy (NACT) is superior remains unanswered.